Spinogenix Reports Positive Initial Results from Phase 2a Alzheimer’s Trial of SPG302

RefinitivMoins d'1 minute de lecture

SPINOGENIX ANNOUNCES POSITIVE FIRST COHORT RESULTS FROM PHASE 2A TRIAL EVALUATING SPG302 FOR ALZHEIMER'S DISEASE

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles